A Study of CaBozantinib in Patients With Advanced or Unresectable Renal cEll cArcinoma
Status:
Completed
Trial end date:
2021-04-08
Target enrollment:
Participant gender:
Summary
This is an open label single arm, multicenter, phase II study designet To assess the
progression free survival (PFS) of cabozantinib in patients pretreated with one
immunocheckpoint inhibitor (CPI) in monotherapy or in combination
Phase:
Phase 2
Details
Lead Sponsor:
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano